VKTX
Live chart
What they do
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
For information only · Important disclosures
Grades vs sector
No sector grades for VKTX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.65 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-4.34 vs trailing $-4.67. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Piotroski F-score 2/9 · last two fiscal years
Altman Z-score 12.1 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $0 | $-359.6M | $-278.7M |
| 2024 | $0 | $-110.0M | $-87.8M |
| 2023 | $0 | $-85.9M | $-73.4M |
| 2022 | $0 | $-68.9M | $-48.4M |
| 2021 | $0 | $-55.0M | $-47.6M |
| 2020 | $0 | $-39.5M | $-21.8M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | -1.21 | -1.10 | +8.8% |
| 2026-04-29 | -0.91 | -1.37 | -50.5% |
| 2026-02-11 | -0.90 | -1.38 | -53.1% |
| 2025-10-22 | -0.67 | -0.81 | -20.1% |
| 2025-07-23 | -0.44 | -0.58 | -31.6% |
| 2025-04-23 | -0.31 | -0.41 | -31.7% |
| 2025-02-05 | -0.27 | -0.32 | -19.7% |
| 2024-10-23 | -0.24 | -0.22 | +8.1% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $0 | – |
| 2026-03-31 | $0 | – |
| 2025-12-31 | $0 | – |
| 2025-09-30 | $0 | – |
| 2025-06-30 | $0 | – |
Rating changes
Third-party analyst actions, not Coteau's views. All rating changes
Insider trades
$609.6K
$710.1K
$4.9M
–
Stats refreshed 2026-10-21 18:28:54 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Beta 0.9 · Oct 21, 2026